Aridis Pharmaceuticals

United States
Los Gatos, California, United States, 95032

Company profile

Aridis Pharmaceuticals company profile

Aridis Pharmaceuticals discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The company is utilizing its proprietary ʎPEXTM and MabIgX technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome infection and to rapidly manufacture monoclonal antibodies (mAbs) for the therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.

Business identity

Contact email
[email protected]
Phone number
4089603822
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2003-01-01, Year

Headquarters

Postal code
95032
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
12
Total equity funding
$67.7M
Last funding
Post IPO Equity / $2.3M / 2023-03-14
Last equity funding
Post IPO Equity / $2.3M
Investors
3
Lead investors
2
Founders
2
Articles
50
Exited on
2018-08-13

Founders and investors

Founders

Eric PatzerVu L. Truong

Lead investors

Bill & Melinda Gates FoundationCystic Fibrosis Foundation

Investors

Bill & Melinda Gates FoundationCystic Fibrosis FoundationEFung Capital